Global obesity is on the rise, and endocrinologists are at the forefront of diagnosing its underlying causes and prescribing treatment plans. Obesity is a complex disease that is associated with various comorbidities, increased mortality, and reduced quality of life. Abdominal obesity is one of the components of metabolic syndrome (MetS), a cluster of risk factors that increases an individual’s risk for chronic conditions such as cardiovascular disease and diabetes.
Learn more about the science of obesity in our 2023 Thematic Issue on Obesity.
The Endocrine Society works to reduce prevalence of obesity through various means, including development and release of scientific statements and practice guidelines, and advocacy for policies and positions that ensure access to affordable treatments. As new obesity medications come to market, the Society will play an important role in educating providers and patients on their optimal usage.
.jpg?la=en&h=241&mw=380&w=380&hash=34D045294BF501EBF9F30D3A795C4576)
Read our “Obesity Playbook," updated April 2025. This educational resource on obesity and health is designed for Congressional staff, covering the latest facts and figures, the state of science, and policy options.
Collaborate with peers on clinical care and research related to obesity. The SIG will discuss topics such as the pharmacoeconomics of obesity, funding opportunities, how NuSH-based AOMs are changing obesity treatment, and engaging with multidisciplinary subspecialties to bridge care gaps in obesity-related comorbidities.
